Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | GUSB | P08236 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6850188 | 0.73 | ADORA3 (0.46) | LMNAMAPTADORA3 | |
| SCHEMBL6848618 | 0.70 | ADORA3 (0.39) | ALDH1A1KDM1ALMNAMAPTADORA3 | |
| SCHEMBL3993972 | 0.69 | ADORA3 (0.41) | ALDH1A1KDM1ALMNAMAPTADORA3 | |
| Bicarbonate SCHEMBL28637012 | 0.59 | ALDH1A1 (0.58) | ALDH1A1GAALMNAMAPTSMN1; SMN2 | |
| SCHEMBL85604 | 0.56 | ALDH1A1 (0.69) | ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL29379039 | 0.56 | ALDH1A1 (0.69) | ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL28252591 | 0.56 | ALDH1A1 (0.69) | ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL28247789 | 0.56 | MEN1 (0.50) | ALDH1A1GAALMNARECQL | |
| SCHEMBL28247167 | 0.56 | MEN1 (0.50) | ALDH1A1GAALMNARECQL | |
| SCHEMBL9315676 | 0.56 | ALDH1A1 (0.49) | ALDH1A1LMNAGUSBMAPTADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720324-B2 | THERAPY FOR EATING DISORDERS, SEXUAL DISORDERS, PSYCHOLOGICAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-20040038855-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2004-02-26 | — | — | US | disclosed |
| US-20030069261-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | H. LUNDBECK A/S (DK) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038855-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | ALDH1A1 1449/4885GAA 1029/4885KDM1A 1104/4885 |
| US-20030069261-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | MCHR1, MCHR2, MC4R | ALDH1A1 1792/4885GAA 316/4885KDM1A 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.